linjc16/ctgov huggingface dataset:
Genotyping FcɣRs Genes of HIV-1 Patients Progressor: Correlation With the Changing Profile of the Infection

Study Overview
=================
Brief Summary
-----------------
This non-interventional study aims to determine whether there is a correlation between the Fc receptor polymorphism (FcR) and the course of the disease following HIV infection.

Official Title
-----------------
Genotyping FcɣRs Genes of HIV-1 Patients Progressor: Correlation With the Changing Profile of the Infection

Conditions
-----------------
HIV Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient aged 18 or older, Patient affiliated to a social security scheme, Informed consent dated and signed by the investigating physician the patient, Patients infected with HIV-1 having progressed in clinical (stage C) or biologically (CD4 nadir <350 / mm3 and viral load> 10,000 copies / ml) Exclusion Criteria: Impossibility of giving the subject informed information (subject in an emergency situation, difficulty in understanding the subject, ...) Subject under safeguard of justice, Subject under tutelage or under curatorship,

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation research between Fc receptor polymorphism (FcR) and the course of disease following HIV infection. |  | After infection, up to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV infection, Fc receptor polymorphism (FcR)
Frequency Analysis of Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if coronary artery disease can be detected using an electronic, acoustic recording instrument. The presence or absence of abnormal pathology will be confirmed by diagnostic angiography as part of the normal patient care at this institution.

Official Title
-----------------
A Single-centered Investigation Into the Frequency Domain Patterns in Vessels of Patients With Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18-89 years old and recommended for a cardiology related angiogram within 24 hours Exclusion Criteria: Any patient less than 18 years of age or greater than 89 years of age. Any patient with any of the following conditions: pregnant or nursing, prior myocardial infarction, left ventricular device, heart transplant, valve replacement, congestive heart failure, atrial fibrillation (non-intermittent), endocarditis or any heart viral or bacterial infection, any patient who has or requires medication or other heart rhythm altering treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to determine if coronary artery disease can be detected using an electronic, acoustic recording instrument | to determine if coronary artery disease can be detected using an electronic, acoustic recording instrument | Baselin | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acoustic, digital, sound, vibration, coronary, auscultation, artery, diagnosis
Retinal Thickness Analysis Using Optical Coherence Tomography

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to characterize and correlate diabetic macular edema (DME), i.e. increased retinal thickness, measured by Optical Coherence Tomograph (OCT), and retinal visual function. The secondary objectives of this study are the analysis and characterization of DME progression over time (between two visits), and the comparison of OCT data obtained with different devices. The results of this study will be used exclusively for scientific purposes.

Official Title
-----------------
Retinal Thickness Analysis Using Optical Coherence Tomography

Conditions
-----------------
Diabetic Retinopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of DR Females or Males Age over 18 years Signed Informed Consent Form Exclusion Criteria: Cataract or other eye disease that may interfere with fundus examinations Vitreous syneresis or posterior vitreous detachment Dilatation of the pupil < 5 mm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| DR<br>Diabetic Retinopathy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal thickness. |  | After visit(s) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Choroidal Thickness |  | After visit(s) |
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.

Official Title
-----------------
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

Conditions
-----------------
Renal Insufficiency, Chronic

Intervention / Treatment
-----------------
* Drug: paricalcitol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Under care of physician at least 2 months (for CKD) Not on active Vitamin D therapy for at least 4 weeks prior If female: Not of childbearing potential, OR Practicing birth control Not breastfeeding If taking phosphate binders, on a stable regimen at least 4 weeks prior For entry into Pretreatment Phase: iPTH at least 120 pg/mL GFR of 15-60 mL/min and no dialysis expected for at least 6 months For entry into Treatment Phase: Average of 2 consecutive iPTH values of at least 150 pg/mL, taken at least 1 day apart (all values not less than 120 pg/mL 2 consecutive corrected serum calcium levels between 8.0-10.0 mg/dL 2 consecutive serum phosphorus levels of not more than 5.2 mg/mL Exclusion Criteria: History of allergic reaction or sensitivity to similar drugs Acute Renal Failure within 12 weeks of study Chronic gastrointestinal disease Spot urine result demonstrating a urine-calcium-to-urine creatinine ratio of greater than 0.2, or a history of renal stones Taken aluminum-containing phosphate binders within last 12 weeks, or requires such medication for more than 3 weeks during study Current malignancy, or clinically significant liver disease Active granulomatous disease (TB, sarcoidosis, etc.) History of drug or alcohol abuse within 6 mos. prior Evidence of poor compliance with diet or medication Received any investigational drug or participated in any device trial within 30 days prior Taking maintenance calcitonin, bisphosphonates, or drugs that may affect calcium or bone metabolism (other than females on stable estrogen and/or progestin therapy) On glucocorticoids for a period of more than 14 days within the last 6 months HIV positive

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: paricalcitol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The efficacy endpoint is achievement of two consecutive > or = 30% decreases from baseline iPTH levels. |  |  |
Airways Dysfunction Following WTC Dust Exposure

Study Overview
=================
Brief Summary
-----------------
In the weeks following the terrorist attacks of September 11, 2001, many patients presented to their physicians with complaints related to exposure to the debris. These included nose and throat complaints (drip, congestion, sore throat), increased GE reflux (heartburn, regurgitation, retrosternal chest burning) and respiratory symptoms (worsening cough, wheezing, shortness of breath, chest tightness, sleep disturbance). In addition, there was a disproportionate rate of self-reported worsening asthma symptoms in patients living in Lower New York 5-9 weeks after the attack; those with exposure to the dust cloud fared worse. The functional abnormalities of firefighters with exposures to dust at the WTC site has been recently described. However, the effects of WTC dust exposure on pulmonary function in residents and workers near the WTC site remain unclear. This study will retrospectively review the charts of all patients referred to the pulmonary function laboratory for evaluation of symptoms following exposure to WTC dust. The main objectives for this study will be to characterize the functional abnormalities in these subjects.

Official Title
-----------------
Airways Dysfunction Following WTC Dust Exposure

Conditions
-----------------
Pulmonary Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-80 referral for pulmonary function evaluation of respiratory symptoms following exposure to WTC dust Exclusion Criteria: inability to perform testing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Distal Airways, Respiratory Function Tests, Oscillometry, World Trade Center Disaster, Environmental Exposure
Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.

Official Title
-----------------
An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women

Conditions
-----------------
Postmenopause

Intervention / Treatment
-----------------
* Drug: Premarin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy postmenopausal women aged 35 to 70 years Nonsmoker or smoker of less than 10 cigarettes per day Exclusion Criteria: History or presence of clotting disorders History or presence of cancer Presence of HIV, hepatitis B or hepatitis C History of drug or alcohol abuse

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Premarin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MPA, bioavailability, bioequivalence, marketed product, Premarin, Medroxyprogesterone acetate, Postmenopausal, vasomotor symptoms
TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the recommended dose of the sustained-release form of BPS (TRK-100STP low dose or high dose) in Japanese patients with CRF (Primary glomerular disease/nephrosclerosis).

Conditions
-----------------
Renal Insufficiency, Chronic

Intervention / Treatment
-----------------
* Drug: Beraprost
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease The patient with progressive CRF Exclusion Criteria: The patient with secondary glomerular disease The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1: Exprimental (TRK-100STP)<br>high dose | Drug: Beraprost<br> <br> |
| Experimental: 2: Exprimental (TRK-100STP)<br>low dose | Drug: Beraprost<br> <br> |
| Placebo Comparator: 3: Placebo Comparator<br>Placebo | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference between the run-in and treatment periods in the slope of the regression line of 1/SCr versus time |  | 50 weeks (Run-in 22weeks, Treatment 28 weeks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Renal Failure, Prostaglandin, Prostacyclin, Glomerular Disease; Nephrosclerosis
Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the safety and benefit of auto-transfusion filtered blood in patients undergoing major surgical oncology procedures.

Detailed Description
-----------------
Homologous blood transfusions during surgical procedures are becoming more challenging, due to lack of adequate reserves and the significant risks of transfusion reactions. Recent advances in the use of patient's own blood (autologous transfusion) has rapidly gained acceptance in major surgical procedures, however due to the requirement for prior planning and the expense of obtaining and storing a patient's blood prior to surgery this alternative is less than ideal. This research study utilizes a third alternative, a technique called intraoperative autotransfusion, which successfully salvages a patient's blood during surgery and reinfuses the blood back into the patient. The blood salvaging device uses a filtration device that successfully filters out all tumor cells to prevent re-infusion of viable cancer cells. This study is designed to demonstrate the safety and benefits of the blood salvaging device on patients undergoing major surgical oncology procedures.

Official Title
-----------------
Phase I/II Evaluation of Intraoperative Autotransfusion Filtration for Major Surgical Oncology Operations

Conditions
-----------------
Pancreaticoduodenectomy, Pancreatectomy, Esophagectomy, Gastrectomy, Hepatectomy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is undergoing a major surgical oncology procedure and has potential for extensive blood loss. Subject is ≥ 18 years of age. Subject or Subject's Legally Authorized Representative (LAR) has signed an IRB-approved informed consent form. Exclusion Criteria: Subject has medical, social, or psychological factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures. Subject is < 18 years of age. Subject or Subject's LAR did not sign IRB-approved informed consent form.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the efficacy of intra-operative ultrasound contrast (Definity) administration |  | Hospital discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cell Saver, Liver Tumors, Liver Cancer, Surgical Oncology, Whipple, Blood Transfusion, Blood salvage, cancer surgery, blood loss
Gait Retraining in Patients With Joint Hypermobility Syndrome/Hypermobile Ehlers Danlos Syndrome

Study Overview
=================
Brief Summary
-----------------
This study evaluates the efficacy of gait retraining with biofeedback in the treatment of neuromusculoskeletal symptoms in patients with Joint Hypermobility Syndrome/Hypermobile Ehlers Danlos Syndrome. Half of participants will participate in a gait retraining program, while the other half will continue standard care.

Official Title
-----------------
Gait Retraining in Patients With Joint Hypermobility Syndrome/Hypermobile Ehlers Danlos Syndrome

Conditions
-----------------
Joint Hypermobility, Ehlers-Danlos Syndrome, Hyperextension Knees

Intervention / Treatment
-----------------
* Other: Gait retraining program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ehlers-Danlos Syndrome Hypermobile type as defined in the 2017 international Ehlers-Danlos Syndrome classification Exclusion Criteria: Other heritable and acquired connective tissue disorders, autoimmune rheumatologic conditions, pregnancy, history of lower limb surgery, cardiovascular limitations, visual limitations.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gait retraining program<br> | Other: Gait retraining program<br>* Supervised gait retraining with verbal and real-time visual feedback.<br>|
| No Intervention: Physical therapy standard care<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee Joint Range of Motion |  | 4-5 weeks |
Comparison of Chest CT Findings Related to COVID-19 With RSNA and BSTI Guidelines

Study Overview
=================
Brief Summary
-----------------
To present the first admission chest computed tomography (CT) findings of patients followed up with a diagnosis of COVID-19, and to compare the two classification systems by evaluating these findings according to the BSTI and RSNA guidelines.

Detailed Description
-----------------
A total of 764 adult patients who were diagnosed with COVID-19 inpatient of researchers' hospital 2020 were included in this study. The findings were recorded as typical, indeterminate, and atypical by the RSNA guidelines and as classical COVID-19, possible COVID-19, indeterminate, and non-COVID-19 by the BSTI classification. The data obtained according to both classification systems were compared with each other.

Official Title
-----------------
Comparison of Chest CT Findings Related to COVID-19 With RSNA and BSTI Guidelines: Correlation Between Radiologists

Conditions
-----------------
Covid19, Infection Viral, CT Scan

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Who had single negative RT-PCR Non-optimal chest CT , insufficient data <18 age of year Thoracic trauma Chest CT Negative Exclusion Criteria: RT-PCR positive and chest CT positive findings At least two RT-PCR negative and chest CT positive findings >18 age of year

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Current study evaluating the success of the guidelines recommended by RSNA and BSTI in detecting COVID-19 disease | Kappa correlation analysis was performed between radiologists in the evaluation of chest CT findings of COVID-19 disease according to BSTI and RSNA guidelines. | 1st week from the moment of first admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronavirus, Computed Thomography, PCR